Open AccessLong non‐coding PANDAR as a novel biomarker in human cancer: A systematic review
Author(s) -
Zou Yifan,
Zhong Yuantang,
Wu Junjie,
Xiao Huizhong,
Zhang Xintao,
Liao Xinhui,
Li Jianfa,
Mao Xuhua,
Liu Yuchen,
Zhang Fuyou
Publication year - 2018
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12422
Subject(s) - biology , rna , microrna , biomarker , cancer , cancer research , long non coding rna , computational biology , gene , genetics
Objectives Long non‐coding RNA s (lnc RNA s) are characterized as a group of RNA s that more than 200 nucleotides in length and have no protein‐coding function. More and more evidences provided that lnc RNA s serve as key molecules in the development of cancer. Deregulation of lnc RNA s functions as either oncogenes or tumour suppressor genes in various diseases. Recently, increasing studies about PANDAR in cancer progression were reported. In our review, we will focus on the current research on the character of PANDAR include the clinical management, tumour progression and molecular mechanisms in human cancers. Materials and methods We summarize and analyze current studies concerning the biological functions and mechanisms of lnc RNA PANDA in tumour development. The related studies were obtained through a systematic search of Pubmed. Results PANDAR was a well‐characterized oncogenic lnc RNA and widely overexpressed in many tumours. PANDAR is upregulated in many types of cancer, including colorectal cancer, lung cancer, renal cell carcinoma, cholangiocarcinoma, osteosarcoma, thyroid cancer and other cancers. Upregulation of PANDAR was significantly associated with advanced tumour weights, TNM stage and overall survival. Furthermore, repressed of PANDAR would restrain proliferation, migration and invasion. Conclusion PANDAR may act as a powerful tumour biomarker for cancer diagnosis and treatment.